Clinical Trials Logo

Clinical Trial Summary

Background: Most people who get COVID-19 seem to recover with no long-term effects. However, some people who recover from acute COVID-19 infections report lingering symptoms. This is called long COVID. Many people with long COVID report symptoms related to the nervous system; these can include problems with fatigue, speech, and memory. Objective: To test motor memory in people with long COVID, compared to healthy volunteers. Eligibility: People aged 18 to 90 years who are also enrolled in study protocol 000089. Healthy adults are also needed. Design: Participants will be screened by telephone. They will confirm they are able to type without discomfort using their nondominant hand. They will confirm they have access to a computer connected to the internet. All study tasks will be done online. Participants will complete 2 tasks in 2 days. Participants will be sent a link to a website. The website will give them instructions. They will place the fingers of their nondominant hand over 4 numbers on the keyboard and type a sequence (eg, 4-1-3-2-4). They will type this sequence as often as they can in 10 seconds. Then they will rest for 10 seconds before repeating the task. They will repeat this pattern for 15 minutes. After they finish the typing task, participants will take a 10-minute questionnaire. They will answer questions about their experiences with COVID-19 and memory issues; they will say which hand they use for tasks such as brushing their teeth or throwing a ball. Participants will get a notice to repeat the typing task 22 hours after they finish the first one. They should complete the second task within 28 hours....


Clinical Trial Description

This study will objectively test procedural motor memory in a group of people with ongoing symptoms following recovery from acute COVID-19 infection. Primary Objective: We will use a keyboard typing task to investigate procedural memory formation (primary endpoint measure) in the context of COVID-19 infection. We have two primary comparisons using the same outcome measure - To compare procedural memory formation between patients with persistent symptoms following COVID-19 infection ( long COVID ) and matched controls who deny symptoms of long COVID (as reported in self-report questionnaires). - To compare procedural memory formation between long COVID patients with memory complaints and long COVID patients without memory complaints. Secondary objectives: Micro-online gains, micro-offline gains, and long-term consolidation (all secondary measures) will be investigated - between patients with long COVID and matched controls. - between long COVID patients with memory complaints and long COVID patients without memory complaints Exploratory objectives: To compare primary and secondary outcome measures between long COVID patients and healthy controls who report prior COVID-19 infection but are not suffering long COVID symptoms Primary endpoint measure: Early procedural memory formation, as measured by the difference in tapping speed (keypresses/second) between the first and last correct training trial of early learning (first 11 trials) in a keyboard task. Secondary endpoint measures: Micro-online learning. Performance improvements within training trials Micro-offline learning (rapid consolidation). Performance improvements during rest intervals interspersed with training periods. Longer-term consolidation (24 hours). Performance improvements between the last training trial of Day 1 and the testing trial of Day 2. We hypothesize that early procedural motor memory learning will be reduced in long COVID patients as compared to healthy controls (primary hypothesis). Seondarily, we hypothesize that micro-online learning, micro-offline learning (rapid consolidation), and longer term consolidation (24 hours) will be also reduced in long COVID patients as compared to controls. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05746624
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact Margaret K Hayward, C.R.N.P.
Phone (301) 451-1335
Email mimi.hayward@nih.gov
Status Recruiting
Phase N/A
Start date November 15, 2021
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2